A research team at Lund University in Sweden has discovered a certain type of cell—foam cells—in patients with the aggressive ...

Glioblastoma is the most common and deadliest form of brain cancer. Patients face a bleak prognosis—the average survival ...

Researchers have identified potential drug targets in glioblastoma cancer stem cells, providing a new approach to treat this ...

A team led by researchers at the University of Toronto has uncovered new targets that could be the key to effectively ...

A team led by researchers at the University of Toronto has uncovered new targets that could be the key to effectively ...

It’ll be a long road to recovery and the treatment is going to be costly. Trevor Reese is 26 years old and is battling ...

The initial trio of patients with glioblastoma have begun treatment with ropidoxuridine in a phase 2 clinical trial, ...

Phase 3 trial results showed that adding veliparib to temozolomide did not significantly improve overall or progression-free survival in newly diagnosed, MGMT-hypermethylated glioblastoma.

Targeting and customizing blood vessels in tumors to increase T cell infiltration and maintain their function may represent the next breakthrough in cancer therapy.

Shuttle Pharmaceuticals has dosed the first three participants in a Phase II trial of Ropidoxuridine for treating ...